The AMR Centre secures £2.3m funding boost

The AMR Centre has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.


Science park leader to talk at UKSPA, Knowledge Exchange meeting & BioIntegrates

Arecor receives regulatory approval to initiate phase I clinical trial for ultra-rapid acting insulin product

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.

Guest blog | Repositive | Two opportunities for biopharmas to enhance their preclinical cancer research at AACR 2019

Three initiatives that are accelerating the development of personalised cancer treatments to the clinic How to overcome the challenges biopharmas face when sourcing preclinical cancer models A recent meta-analysis of clinical trials put the success rate for therapies in cancer indications progressing from first-in-human to approval at just 3.4%. That means a staggering 96.6% of cancer therapies fail during the clinical stages of drug development. In this blog post we discuss one of the key issues hindering preclinical cancer drug development and explore the latest initiatives that are helping to advance new cancer treatments to the clinic.

CEO Update | Monday 18 March 2019

An interesting first at the WHO this week as it convenes its first expert advisory committee on developing global standards for the governance and oversight of human genome editing. I’ve pulled some thoughts together on it, the Nature letter that made headlines last week and a UK perspective in a blog post here. Parliament will again focus on Brexit this week, in the run up to the European Council meeting on Thursday and Friday. There may, or may not, be another parliamentary vote ahead of the discussion on Thursday where the Prime Minister is expected to ask for an extension to the Article 50 period.

The WHO, gene editing and ethics | BIA CEO, Steve Bates OBE

The World Health Organisation is today convening its first expert advisory committee on developing global standards for the governance and oversight of human genome editing. The aim of the two-day meeting, in Geneva, is to examine the scientific, ethical, social and legal challenges of gene-editing and create guidelines and standards for it. The meeting follows a call last week by some 16 leading scientists from 7 countries: USA; China; Canada; France; Germany; Italy and New Zealand for a global moratorium on heritable genome editing.

Apply to present at the 2019 Babraham Investor Conference

Babraham Research Campus is offering companies seeking funding the opportunity to present at its 10th investor conference

N-Site Life Sciences Knowledge Portal is now free for all subscribers – new expert guidance updates available

N-Site is a unique knowledge portal which provides expert insight and expertise for organisations, professionals and academics in the life sciences sector. This resource is now free to all subscribers, reflecting our intention for this resource to be used by as many as possible, and offers over 85 Guidance Notes from FTI Consulting, Gill Jennings & Every and Taylor Wessing on the key issues affecting companies in the sector.

Guest Blog | SynbiTECH 2019

SynbiTECH 2019 | June 24-25th, QEII Centre, London SynbiTECH 2019 is the only international forum focused on synthetic biology, taking place in the UK in 2019. The event will address the opportunities and challenges associated with building a multibillion-dollar synthetic biology industry that will underpin the fast-growing bioeconomy. The event is designed for senior business leaders from start-ups to multinationals, investors and policy makers.

The Spring Statement

The Spring Statement is the Chancellor’s lesser Parliamentary set piece of the year, behind the Budget in the autumn. But today’s was overshadowed to a much greater extent by the ramifications of MPs rejecting the Government’s Brexit deal for a second time the night before. Another headache for Philip Hammond was the impossibility of knowing what the UK’s balance sheet will look like next month or the month after that, or the month after that, as a result of the Brexit uncertainty. The statement today was therefore a bit of a damp squib but did include some welcome announcements on an investment in genomics and the treatment of researchers in the immigration system. We also found out that, subject to Brexit, the Spending Review will kick off before summer and cover three years.